共 126 条
[1]
Aaronson NK(1993)The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365-376
[2]
Ahmedzai S(1994)The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life Eur J Cancer 30A 635-642
[3]
Bergman B(2013)The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review Anticancer Res 33 3553-3561
[4]
Bullinger M(2006)Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study J Clin Oncol 24 1435-1442
[5]
Cull A(2004)Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 257-260
[6]
Duez NJ(2008)Population based epidemiology and prognosis of mesothelioma in Leeds, UK Thorax 63 435-439
[7]
Filiberti A(2011)Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden Clin Cancer Res 17 1181-1189
[8]
Flechtner H(2005)Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein Hematol Oncol Clin North Am 19 1025-1040
[9]
Fleishman SB(1997)Modeling valuations for EuroQol health states Med Care 35 1095-1108
[10]
de Haes JC(2003)Fatigue and quality of life: lessons from the real world Oncologist 8 5-9